SAFETY AND EFFICACY OF 24 WEEKS TREATMENT WITH ORAL TLR8 AGONIST, SELGANTOLIMOD, IN VIREMIC ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2 STUDY

被引：0

作者：

Janssen, Harry L. A. ^{[1
]}

Lim, Young-Suk ^{[2
]}

Kim, Hyung Joon ^{[3
]}

Tseng, Cheng-Hao ^{[4
]}

Coffin, Carla S. ^{[5
]}

Elkhashab, Magdy ^{[6
]}

Ahn, Sang Hoon ^{[7
]}

Nguyen, Anh-Hoa ^{[8
]}

Chen, Diana ^{[8
]}

Wallin, Jeffrey ^{[8
]}

Tan, Susanna ^{[8
]}

Yang, Jenny C. ^{[8
]}

Gagger, Anuj ^{[8
]}

Brainard, Diana M. ^{[8
]}

Fung, Scott K. ^{[9
]}

Kim, Yoon Jun ^{[10
,11
]}

Kao, Jia-Horng ^{[12
]}

Chuang, Wan-Long ^{[13
]}

机构：

[1] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto Ctr Liver Dis, Toronto, ON, Canada

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Gastroenterol, Seoul, South Korea

[3] Chung Ang Univ, Coll Med, Seoul, South Korea

[4] E Da Hosp, Kaohsiung, Taiwan

[5] Univ Calgary, Gastroenterol & Hepatol, Calgary, AB, Canada

[6] Toronto Liver Ctr, Res, Toronto, ON, Canada

[7] Yonsei Univ, Coll Med, Gastroenterol, Severance Hosp, Seoul, South Korea

[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[9] Univ Toronto, Toronto, ON, Canada

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ Hosp, Liver Res Inst, Seoul, South Korea

[12] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[13] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

829

引用

页码：506A / 507A

页数：2

共 50 条

[1] Safety and Efficacy of Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients With Chronic Hepatitis B
Janssen, Harry
Lim, Young-Suk
Kim, Hyung Joon
Tseng, Cheng-Hao
Coffin, Carla
Elkashab, Magdy
Ahn, Sang Hoon
Nguyen, Anh-Hoa
Chen, Diana
Wallin, Jeffrey
Tan, Susana
Yang, Jenny
Gaggar, Anuj
Brainard, Diana
Fung, Scott
Kim, Yoon Jun
Kao, Jia-Horng
Chuang, Wan-Long
Brooks, Anna
Dunbar, Rod
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S865 - S865
[2] Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B
Janssen, Harry L. A.
Lim, Young-Suk
Kim, Hyung Joon
Tseng, Cheng-Hao
Coffin, Carla S.
Elkashab, Magdy
Ahn, Sang Hoon
Anh-Hoa Nguyen
Chen, Diana
Wallin, Jeffrey
Tan, Susanna
Yang, Jenny
Gaggar, Anuj
Brainard, Diana
Fung, Scott
Kim, Yoon Jun
Kao, Jia-Horng
Chuang, Wan-Long
Brooks, Anna
Dunbar, P. Rod
[J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S757 - S758
[3] Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study
Gane, Edward
Dunbar, P. Rod
Brooks, Anna
Zhao, Yang
Tan, Susanna
Lau, Audrey
Yang, Jenny
Gaggar, Anuj
Subramanian, Mani
Kottilil, Shyamasundaran
Tang, Lydia
[J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S52 - S52
[4] Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
Gane, Edward J.
Kim, Hyung Joon
Visvanathan, Kumar
Kim, Yoon Jun
Anh-Hoa Nguyen
Wallin, Jeffrey J.
Chen, Diana Y.
McDonald, Circe
Arora, Priyanka
Tan, Susanna K.
Gaggar, Anuj
Roberts, Stuart K.
Lim, Young-Suk
[J]. HEPATOLOGY, 2021, 74 (04) : 1737 - 1749
[5] Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression
Gane, Edward J.
Dunbar, P. Rod
Brooks, Anna E.
Zhang, Fangqiu
Chen, Diana
Wallin, Jeffrey J.
van Buuren, Nicholas
Arora, Priyanka
Fletcher, Simon P.
Tan, Susanna K.
Yang, Jenny C.
Gaggar, Anuj
Kottilil, Shyamasundaran
Tang, Lydia
[J]. JOURNAL OF HEPATOLOGY, 2023, 78 (03) : 513 - 523
[6] Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
Amin, Oliver E.
Colbeck, Emily J.
Daffis, Stephane
Khan, Shahzada
Ramakrishnan, Dhivya
Pattabiraman, Divya
Chu, Ruth
Steuer, Holly Micolochick
Lehar, Sophie
Peiser, Leanne
Palazzo, Adam
Frey, Christian
Davies, Jessica
Javanbakht, Hassan
Rosenberg, William M. C.
Fletcher, Simon P.
Maini, Mala K.
Pallett, Laura J.
[J]. HEPATOLOGY, 2021, 74 (01) : 55 - 71
[7] EFFICACY AND SAFETY OF ORAL TLR8 AGONIST GS-9688 IN VIRALLY-SUPPRESSED ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTI-CENTER STUDY
Gane, Edward J.
Zhao, Yang
Tan, Susanna
Lau, Audrey H.
Gaggar, Anuj
Subramanian, Mani
Kottilil, Shyam
Tang, Lydia
[J]. HEPATOLOGY, 2019, 70 : 435A - 436A
[8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study
Lim, Young-Suk
Hui, Aric J.
Jang, Jeong-Won
Tak, Won-Young
Ahn, Sang Hoon
Jang, Byoung Kuk
Tsang, Tak Yin Owen
Kim, Won
Yang, Jenny
Chen, Diana
McDonald, Circe
Zhang, Liao
Gaggar, Anuj
Gao, Bing
Byun, Kwan Soo
Lee, Kwan Sik
Yim, Hyung Joon
Chan, Henry L. Y.
[J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S757 - S757
[9] Safety, Pharmacokinetics and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study
Gane, Edward J.
Kim, Hyung Joon
Visvanathan, Kumar
Kim, Yoon Jun
Nguyen, Anh-Hoa
Joshi, Adarsh
Reyes, Maribel
Lau, Audrey H.
Gaggar, Anuj
Subramanian, Mani
Roberts, Stuart Keith
Lim, Young-Suk
[J]. HEPATOLOGY, 2018, 68 : 238A - 239A
[10] In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B
Amin, Oliver E.
Colbeck, Emily
Daffis, Stephane
Pattabiraman, Divya
Sitali, Colette
Rosenberg, William
Fletcher, Simon
Maini, Mala
Pallett, Laura J.
[J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E445 - E445

← 1 2 3 4 5 →